ProfileGDS5678 / 1422964_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 93% 92% 90% 89% 90% 93% 94% 92% 91% 92% 92% 92% 92% 92% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.7797293
GSM967853U87-EV human glioblastoma xenograft - Control 27.7084292
GSM967854U87-EV human glioblastoma xenograft - Control 37.335290
GSM967855U87-EV human glioblastoma xenograft - Control 47.1471889
GSM967856U87-EV human glioblastoma xenograft - Control 57.259590
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.5452593
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.8425594
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.5137492
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.324491
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.7404392
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.64492
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.608792
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.537192
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.5321892